-
[show abstract]
[hide abstract]
ABSTRACT: This study aimed to assess the metabolic parameters and androgen concentration in the cord blood of newborns of mothers with polycystic ovary syndrome (PCOS) in comparison with controls.
This cross-sectional study was conducted in 2010-2011 in Isfahan, Iran. Biochemical tests were conducted on 40 infants, born from singleton pregnancies in women with PCOS and an equal number of controls.
The mean weight gain during pregnancy was higher in women with PCOS than in controls (16.02 ± 4.39 vs. 9.10 ± 2.20 kg, respectively, P < 0.0001). The mean birth weight was lower in newborns of mothers with PCOS than in controls (2905.25 ± 415.59 vs. 3223.25 ± 425.02 vs. grams, respectively, P = 0.001). The mean testosterone was higher in cord blood of newborns of PCOS women than in controls (5.58 ± 3.20 vs. 2.28 ± 0.62 pg/ml, P < 0.0001). Triglycerides and LDL-C were lower in cord blood of newborns, born from PCOS women than in controls (P = 0.001). The birth weight of the newborns of PCOS mothers was negatively correlated to free testosterone of cord blood (R = -0. 26, P = 0.04).
The metabolic aberration in PCOS might influence fetal birth weight and cord blood lipid profile. These disorders may be caused by an exposure to elevated testosterone level during fetal life. The offspring of PCOS women may be at higher risk for chronic diseases in later life. The clinical impact of our findings should be confirmed in future longitudinal studies.
Journal of research in medical sciences 03/2012; 17(3):207-11. · 0.46 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study was performed to evaluate and compare the placental pathology in patients with severe pre-eclampsia (PE) and HELLP syndrome. Moreover, neonatal birth weight was compared between the two groups.
This cross-sectional prospective study was conducted in Alzahra and Beheshti Hospitals (Isfahan, Iran) between 2007 and 2009. Placentas from 32 patients having severe pre-eclampsia without HELLP (referred to as preeclampsia group) and 25 patients having severe preeclampsia with HELLP syndrome (referred to as HELLP group) were evaluated. The studied parameters included placental weight, chorioamnionitis (either acute or chronic), retroplacental hematoma, placental infarction, intervillous thrombosis, and decidual arteriopathy. Birth weight adjusted for gestational age was also compared between the two groups.
We found statistically more significant frequency of retroplacental hematoma in the PE group compared to the HELLP group (P value 0.00). Despite the relatively high frequency of accelerated villous maturation and decidual arteriopathy in both groups, the difference between the two groups regarding these two parameters was not statistically significant. Other placental features did not show any significant difference between the two groups either. The frequency of small for gestational age births showed no statistically significant difference between the two groups.
Retroplacental hematoma was the only placental pathology that showed statistically significant different frequencies between the two groups. Although this may suggest different underlying pathogenetic mechanisms in these two conditions, further studies are needed to confirm this hypothesis.
Archives of Gynecology 06/2011; 285(1):175-81. · 0.91 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Polycystic ovary syndrome (PCOS) is associated with metabolic abnormalities which are also parts of metabolic syndrome (MetS). It is debated whether all women with PCOS should be screened for MetS and Insulin resistance (IR), since they may vary in terms of PCOS phenotype, ethnicity and age. This large scale study aimed to determine the prevalence of MetS among Iranian women diagnosed with different phenotypic subgroups of PCOS based on the Rotterdam criteria.
This study was conducted from January 2006 to June 2008 in Isfahan, Iran. The study population comprised females diagnosed with PCOS referred to the infertility clinic. The subjects were divided into for subgroups according to different phenotypes of PCOS based on the Rotterdam criteria. They underwent metabolic screening according to NCEP ATP III guidelines and IR screening based on homeostasis model assessment (HOMA) of insulin resistance.
The prevalence of MetS and IR were 24.9% and 24.3%, respectively. A significant difference in the prevalence of MetS was documented between anovulatory women having PCOS with or without hyperandrogenism (23.1% and 13.9%, respectively; P = 0.001). Likewise, in PCOS women with hyperandrogenism, the MetS prevalence differed among those with or without polycystic ovary (23.1% and 63.8%, respectively; P = 0.001).
The prevalence of MetS and IR varies between the phenotypic subgroups of PCOS. Hyperandrogenemia PCOS phenotypes of Iranian women, in particular those without sonographic polycystic ovary, are highly at risk of MetS and IR.
Journal of research in medical sciences 06/2011; 16(6):763-9. · 0.46 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Phytoestrogens are a group of plants derived compounds with weekly estrogen effect that appear to have protective effects on metabolic and hormonal abnormalities of women with polycystic ovary syndrome (PCOS). So the aim of this study was to investigate the effect of soy phytoestrogens on reproductive hormones and lipid profiles in PCOS women.
In this quasi-randomized trial, 146 subjects with PCOS were divided into two groups; the experimental group who received Genistein (Bergamon, Italy) 18 mg twice a day orally and the control group that received similar capsules with cellulose for 3 months. Hormonal features and lipid profiles were measured before and after 3 months of supplement therapy.
After 3 months of supplement therapy there were no statistically significant differences in high density lipoprotein cholesterol (HDL) and follicle stimulating hormone (FSH) serum levels in Genistein and placebo group before and after treatment; however serum levels of luteinizing hormone (LH), triglyceride (TG), low density lipoprotein cholesterol (LDL), dehydroepiandrostrone sulfate (DHEAS) and testosterone were significantly decreased after 3 months therapy in Genistein group.
Genistein consumption may prevent cardiovascular and metabolic disorders in PCOS patients by improving their reproductive hormonal and lipid profiles.
Journal of research in medical sciences 03/2011; 16(3):297-302. · 0.46 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study aimed to determine the prevalence of polycystic ovary syndrome (PCOS) in Iranian women based on different diagnostic criteria.
This cross-sectional study was conducted in 2009 in Isfahan, Iran among females referred to the mandatory pre-marriage screening clinic. Menstrual irregularity was assessed as the presence of chronic amenorrhea or a menstrual cycle length of less than 21 days or more than 35 days, or more than four days of variation between cycles. Clinical hyperandrogenism was assessed as the self-reported degree of hirsutism using the modified Ferriman Gallwey (mF-G) scoring method based on a chart displaying degree of hair growth in nine regions. Those participants who reported menstrual irregularity and/or who had an mF-G score of ≥ 8 were invited for a clinical examination. Those who did not have these criteria were not further evaluated and were deemed not to have PCOS. Participants with abnormal findings underwent blood test and abdominal sonography of their ovaries. In those with hirsutism, serum was obtained on the 22(nd)-24(th) day of the cycle for the measurement of progesterone; free testosterone was measured in those with menstrual irregularity.
The estimated prevalence of PCOS was 7% based on the NIH criteria, 15.2% under the Rotterdam criteria, and 7.92% according to the AES criteria.
The Rotterdam prevalence estimates were double those obtained with the NIH criteria. This study can be used for international comparisons because it was conducted on a representative sample of females using different criteria for the definition of PCOS.
Endokrynologia Polska 01/2011; 62(3):238-42. · 1.24 Impact Factor
